Sotera Health (NASDAQ:SHC) Shares Sold by Barclays PLC

Barclays PLC cut its stake in Sotera Health (NASDAQ:SHC - Free Report) by 68.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 149,731 shares of the company's stock after selling 323,866 shares during the period. Barclays PLC owned about 0.05% of Sotera Health worth $2,050,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Sotera Health by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 14,923,546 shares of the company's stock valued at $204,154,000 after buying an additional 173,341 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Sotera Health by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 2,780,445 shares of the company's stock worth $38,048,000 after acquiring an additional 25,054 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Sotera Health by 45.1% during the fourth quarter. Bank of New York Mellon Corp now owns 1,630,736 shares of the company's stock worth $22,308,000 after purchasing an additional 507,147 shares during the last quarter. Norges Bank acquired a new position in shares of Sotera Health in the 4th quarter valued at $12,764,000. Finally, Rhumbline Advisers grew its holdings in shares of Sotera Health by 3.8% during the fourth quarter. Rhumbline Advisers now owns 399,171 shares of the company's stock worth $5,461,000 after purchasing an additional 14,616 shares during the last quarter. 91.03% of the stock is owned by institutional investors and hedge funds.

Sotera Health Stock Performance

Shares of SHC stock traded up $0.31 during trading hours on Wednesday, reaching $13.16. 1,198,956 shares of the company's stock were exchanged, compared to its average volume of 1,210,160. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. Sotera Health has a 1 year low of $9.53 and a 1 year high of $17.08. The company has a market cap of $3.73 billion, a P/E ratio of 52.62 and a beta of 1.88. The company's 50 day moving average is $11.39 and its two-hundred day moving average is $12.98.

Sotera Health (NASDAQ:SHC - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.12 by $0.02. The company had revenue of $254.52 million for the quarter, compared to analyst estimates of $245.56 million. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The business's revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.13 EPS. Equities research analysts anticipate that Sotera Health will post 0.61 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on SHC. Piper Sandler decreased their target price on Sotera Health from $15.00 to $13.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Barclays reduced their target price on shares of Sotera Health from $16.00 to $12.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Finally, The Goldman Sachs Group upgraded Sotera Health from a "neutral" rating to a "buy" rating and lifted their target price for the company from $14.00 to $17.00 in a research note on Monday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $15.80.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.